HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2
- PMID: 39375512
- PMCID: PMC11618360
- DOI: 10.1038/s41418-024-01392-5
HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2
Abstract
Glucose sensing and metabolic adaptation to glucose availability in the tumor microenvironment are critical for cancer development. Here we show that HKDC1, a hexokinase highly expressed in cancer associated with poor prognosis, functions as a glucose sensor that alters its stability in response to environmental glucose. The glucose-sensing domain is located between amino acids 751-917, with Ser896 as a key residue that regulates HKDC1 stability by affecting Lys620 ubiquitination. This sensing mechanism enables cellular adaptation to glucose starvation by promoting mitochondrial fatty acid utilization. Furthermore, HKDC1 promotes tumor growth by sequestering prohibitin 2 (PHB2) to disable its suppressive effect on SP1, thus promoting the expression of pro-oncogenic molecules. Abrogation of HKDC1 by genetic knockout or by glucose depletion releases PHB2, leading to suppression of cancer cell proliferation and inhibition of tumor growth. Our study reveals a previously unrecognized role of HKDC1 in glucose sensing and metabolic adaptation, and identifies HKDC1 as a potential therapeutic target.
© 2024. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethics approval: All experiments with animals were approved by the Animal Care and Use Committee of Sun Yat-sen University Cancer Center (Approve number: L102012020070B); this research did not involve human subjects study.
References
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. - PubMed
-
- Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46. - PubMed
-
- Glorieux C, Liu S, Trachootham D, Huang P. Targeting ROS in cancer: rationale and strategies. Nat Rev Drug Discov. 2024;23:583–606. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
